AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently Amended) A compound selected from the group consisting of compounds of formula (I)



(I)

wherein

U	is O or a lone pair;
V	is ~~O, S,~~ $-CH_2-$, -CH=CH-, or -C≡C-;
W	is CO, COO, $CONR^1$, CSO, $CSNR^1$, SO_2, or SO_2NR^1;
m and n	are each integers from 0 to 7, with the provisos that m+n is 0 to 7 and m is not 0 when V is O or S;
A^1	is H, lower-alkyl, hydroxy-lower-alkyl, or lower-alkenyl; and
A^2	is lower-alkyl, cycloalkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted by R^2~~, or~~
~~A^1 and A^2~~	~~bond together to form $-A^1-A^2-$, wherein $-A^1-A^2-$ is lower-alkylene or lower-alkenylene, optionally substituted by R^2, in which one $-CH_2-$ group of $-A^1-A^2-$ is optionally replaced by NR^3, S, or O~~;
A^3 and A^4	are each hydrogen or lower-alkyl~~, or~~
~~A^3 and A^4~~	~~bond together to form $-A^3-A^4-$, wherein $-A^3-A^4-$ is $(CH_2)_{2-5}$ optionally mono- or multiply-substituted by lower-alkyl~~;
A^5	is H, lower-alkyl, lower-alkenyl, or aryl-lower-alkyl;
A^6	is lower-alkyl, cycloalkyl, aryl, aryl-lower-alkyl, heteroaryl, heteroaryl-lower-alkyl, lower-alkoxy-carbonyl-lower-alkyl;

R^2 is hydroxy, hydroxy-lower-alkyl, lower-alkoxy, lower-alkoxycarbonyl, $N(R^4,R^5)$, or thio-lower-alkoxy; and

R^1, R^3, R^4 and R^5 independently from each other are hydrogen or lower-alkyl; ~~and when A^1 is not bonded to A^2 and A^3 is not bonded to A^4, A^1 and A^3 optionally bond together to form $-A^1-A^3-$, wherein $-A^1-A^3-$ is lower-alkylene or lower-alkenylene, optionally substituted by R^2, in which one $-CH_2-$ group of $-A^1-A^3-$ is optionally replaced by NR^3, S, or O;~~

pharmaceutically acceptable salts of the compounds of formula (I), and

pharmaceutically acceptable esters of the compounds of formula (I).

2. (Canceled)

3. (Original) The compound according to claim 1, selected from the group consisting of compounds of formula (Ia):



(Ia)

wherein U, V, W, m, n, A^1, A^2, A^3, A^4, A^5 and A^6 are as defined in claim 1;

pharmaceutically acceptable salts of the compounds of formula (Ia); and

pharmaceutically acceptable esters of the compounds of formula (Ia).

4. (Original) The compound according to claim 1, wherein U is a lone pair.

5. (Canceled)

6. (Original) The compound according to claim 4, wherein V is $-CH_2-$.

7. (Original) The compound according to claim 4, wherein V is -C=C-.

8. (Original) The compound according to claim 4, wherein V is -C≡C-.

9. (Original) The compound according to claim 4, wherein W is CO, COO, $CONR^1$, $CSNR^1$, SO_2 or SO_2NR^1 and R^1 is hydrogen.

10. (Original) The compound according to claim 9, wherein W is COO or SO_2.

11. (Original) The compound according to claim 10, wherein n is 0.

12. (Original) The compound according to claim 10, wherein n is 1.

13. (Original) The compound according to claim 10, wherein m is 1 to 6.

14. (Original) The compound according to claims 10, wherein m is 0 and V is -C=C- or -C≡C-.

15. (Original) The compound according to claim 10, wherein A^1 is H, methyl, ethyl, isopropyl, 2-hydroxy-ethyl, or 2-propenyl.

16. (Original) The compound according to claim 10, wherein A^2 is lower-alkyl, cycloalkyl-lower-alkyl, or lower-alkenyl, optionally substituted with R2, wherein R2 is hydroxy, methoxy, or ethoxycarbonyl.

17. (Original) The compound according to claim 16, wherein A^2 is methyl, ethyl, 2-hydroxy-ethyl, 2-propenyl, propyl or isopropyl.

Claims 18-20. (Canceled)

21. (Original) The compound according to claim 10, wherein A^3 is hydrogen.

22. (Original) The compound according to claim 10, wherein A^4 is hydrogen.

23. (Canceled)

24. (Original) The compound according to claim 10, wherein A^5 is H, lower-alkyl, lower-alkenyl, or benzyl optionally substituted with halogen.

25. (Original) The compounds according to claim 24, wherein A^5 is methyl or ethyl.

26. (Original) The compound according to claim 25, wherein A^6 is lower-alkyl, cycloalkyl, phenyl, naphthyl, phenyl-lower-alkyl, pyridyl, indolyl, indolinyl, thienyl, thienyl-methylene, furyl-methylene, benzodioxyl, chinolyl, isoxazolyl, or imidazolyl, optionally substituted by one or more substituents selected from the group consisting of lower-alkyl, lower-alkoxy, lower-alkylcarbonyl, lower-alkoxycarbonyl, fluorine, chlorine, bromine, CN, CF_3, NO_2, or $N(R^6,R^7)$, wherein R^6 and R^7 independently from each other are hydrogen or lower-alkyl.

27. (Original) The compound according to claim 26, wherein A^6 is phenyl optionally substituted by one or more substituents selected from the group consisting of fluorine, chlorine, bromine, and CF_3.

28. (Original) The compound according to claim 27, wherein A^6 is 4-chloro-phenyl, 4-bromo-phenyl, or 4-trifluoromethyl-phenyl.

29. (Original) The compound according to claim 28, wherein A^1 is H, lower alkyl or hydroxy-lower alkyl and A^2 is lower alkyl, hydroxy-lower alkyl or lower alkenyl.

30. (Original) The compound according to claim 29, wherein A^3 and A^4 are hydrogen.

Claims 31-33. (Canceled)

34. (Original) The compound according to claim 30, wherein V is $-CH_2-$.

35. (Original) The compound according to claim 30, wherein V is -C=C-.

36. (Original) The compound according to claim 30, wherein V is -C≡C-.

37. (Currently amended) A compound selected from the group consisting of compounds of formula (Ib):



(Ib)

wherein

V is ~~O, S,~~ $-CH_2-$, -CH=CH-, or -C≡C-;

W is COO or SO_2;

p is an integer from 0 to 7, with the proviso that p is not 0 when V is O or S;

A^{11} is H, lower-alkyl, or hydroxy-lower-alkyl; ~~and~~

A^{12} is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl~~, or~~

~~A^{11} and A^{12} bond together to form $-A^{11}-A^{12}-$, wherein $-A^{11}-A^{12}-$ is lower alkylene~~;

A^{13} and A^{14} are each hydrogen ~~or bond together to form $-A^{13}-A^{14}-$, wherein $-A^{13}-A^{14}-$ is $-(CH_2)_{2-5}-$~~;

A^{15} is lower-alkyl; and

A^{16} is halogen or trifluoromethyl;

pharmaceutically acceptable salts of the compounds of formula (Ib), and

pharmaceutically acceptable esters of the compounds of formula(Ib).

38. (Previously amended) The compound according to claim 37, wherein A^{11} is H, lower-alkyl, or hydroxy-lower-alkyl and A^{12} is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl.

39. (Original) The compound according to claim 38, selected from the group consisting of trans-N-{4-[2-(1-dimethylamino-cyclopropyl)-ethoxy]-cyclohexyl}-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

40. (Original) The compound according to claim 37, whereon A^{13} and A^{14} are hydrogen.

41. (Original) The compound according to claim 40, selected from the group consisting of trans-4-bromo-N-methyl-N-[4-(2-piperidin-1-yl-ethoxy)-cyclohexyl]-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

42. (Original) The compound according to claim 40, selected from the group consisting of trans-methyl-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

43. (Original) The compound according to claim 40, selected from the group consisting of trans-N-methyl-N-[4-(4-piperidin-1-yl-butyl)-cyclohexyl]-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

44. (Original) The compound according to claim 40, selected from the group consisting of trans-methyl-[4-(5-piperidin-1-yl-pentyl)-cyclohexyl]-carbamic acid 4-cloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

45. (Original) The compound according to claim 40, wherein A^{11} is H, lower-alkyl, or hydroxy-lower-alkyl and A^{12} is lower-alkyl, hydroxy-lower alkyl, or lower-alkenyl.

Claims 46-62. (Canceled).

63. (Original) The compound according to claim 45, wherein V is $-CH_2-$.

64. (Original) The compound according to claim 63, wherein W is COO.

65. (Original) The compound according to claim 64, wherein A^{11} is H.

66. (Original) The compound according to claim 65, selected from the group consisting of trans-methyl-[4-(5-methylamino-pentyl)-cyclohexyl]-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

67. (Original) The compound according to claim 64, wherein A^{11} is methyl.

68. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-trifluoromethyl-

phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

69. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

70. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

71. (Original) The compound according to claim 67, selected from the group consisting of trans-{4-[4-(allyl-methyl-amino)-butyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

72. (Original) The compound according to claim 64, wherein A^{11} is ethyl.

73. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-trifluoromethyl-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

74. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-methyl-carbamic acid 4-bromo-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

75. (Original) The compound according to claim 72, selected from the group consisting of trans-(4-{3-[ethyl-(2-hydroxy-ethyl)-amino]-propyl}-cyclohexyl)-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

76. (Original) The compound according to claim 63, wherein W is SO_2.

77. (Original) The compound according to claim 76, selected from the group consisting of trans-N-{4-[5-(allyl-methyl-amino)-pentyl]-cyclohexyl}-N-methyl-4-trifluoromethyl-

benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

78. (Original) The compound according to claim 76, selected from the group consisting of trans-N-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pentyl}-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

79. (Original) The compound according to claim 45, wherein V is -C=C-.

80. (Original) The compound according to claim 79, wherein W is COO.

81. (Original) The compound according to claim 79, wherein W is SO_2.

82. (Original) The compound according to claim 81, selected from the group consisting of trans-(1E)-N-methyl-N-{4-[3-(methyl-propyl-amino)-propenyl]-cyclohexyl}-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

83. (Original) The compound according to claim 81, selected from the group consisting of trans-(1E)-N-(4-{3-[ethyl-(2-hydroxy-ethyl)-amino]-propenyl}-cyclohexyl)-N-methyl-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

84. (Original) The compound according to claim 45, wherein V is -C≡C-.

85. (Original) The compound according to claim 84, wherein W is COO.

86. (Original) The compound according to claim 85, selected from the group consisting of trans-{4-[3-(allyl-methyl-amino)-prop-1-ynyl]-cyclohexyl}-methyl-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

87. (Original) The compound according to claim 85, selected from the group consisting of trans-(4-{5-[ethyl-(2-hydroxy-ethyl)-amino]-pent-1-ynyl}-cyclohexyl)-methyl-carbamic acid 4-

chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

88. (Original) The compound according to claim 85, selected from the group consisting of trans-methyl-{4-[3-(methyl-propyl-amino)-prop-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

89. (Original) The compound according to claim 84, wherein W is SO_2.

90. (Original) The compound according to claim 89, selected from the group consisting of trans-N-[4-(4-dimethylamino-but-1-ynyl)-cyclohexyl]-N-methyl-4-trifluoromethyl-benzene-sulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

91. (Original) The compound according to claim 89, selected from the group consisting of trans-N-methyl-N-{4-[4-(methyl-propyl-amino)-but-1-ynyl]-cyclohexyl}-4-trifluoromethyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

92. (Original) The compound according to claim 89, selected from the group consisting of trans-N-(4-{4-[ethyl-(2-hydroxy-ethyl)-amino]-but-1-ynyl}-cyclohexyl)-N-methyl-4-trifluoro-methyl-benzenesulfonamide, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

93. (Original) A process for the manufacture of a compound according to claim 1, comprising reacting a compound of formula (II):



(II)

wherein

A^5 is as defined in claim 1,

Z is a group $(A^1, A^2)N\text{-}C(A^3,A^4)\text{-}(CH_2)_m\text{-}V\text{-}(CH_2)_n$ or $HO\text{-}(CH_2)_n$, wherein A^1, A^2, A^3, A^4, V, m and n are defined as in claim 1,

with ClSO2-A^6, ClCOO-A^6, ClCSO-A^6, OCN-A^6, SCN-A^6, HOOC-A^6, or $ClSO_2NR^1$-A^6, wherein A^6 is as defined in claim 1.

94. (Previously added) A pharmaceutical composition comprising a compound according to claim 1 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

95. (Previously added) The compound according to claim 36, selected from the group consisting of trans-methyl-{4-[5-(methyl-propyl-amino)-pent-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

96. (Previously added) A pharmaceutical composition comprising a compound according to claim 95 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.

97. (Previously added) The compound according to claim 85, selected from the group consisting of trans-methyl-{4-[5-(methyl-propyl-amino)-pent-1-ynyl]-cyclohexyl}-carbamic acid 4-chloro-phenyl ester, pharmaceutically acceptable salts thereof and pharmaceutically acceptable esters thereof.

98. (Previously added) A pharmaceutical composition comprising a compound according to claim 97 and at least one of a pharmaceutically acceptable carrier or a pharmaceutically acceptable adjuvant.